The SURMOUNT-1 study laid the scientific foundation for the use of tirzepatide in obesity. A detailed analysis of the game-changing results.
Published in the New England Journal of Medicine in July 2022, the SURMOUNT-1 study is the pivotal clinical trial that led to the authorization of tirzepatide (Zepbound) for the treatment of obesity. With 2,539 participants followed for 72 weeks, this study set unprecedented weight loss records for a pharmacological treatment. A complete breakdown.
Study Design: Rigorous Methodology
SURMOUNT-1 was a randomized, double-blind, placebo-controlled trial conducted in 119 centers across 9 countries. The inclusion criteria were precise: adults with a BMI ≥ 30 kg/m² (or ≥ 27 with at least one weight-related comorbidity), without type 2 diabetes. Participants were randomized into 4 groups: tirzepatide 5 mg, 10 mg, 15 mg, or placebo, all administered as weekly subcutaneous injections.
All participants benefited from a lifestyle modification program including a 500 kcal/day caloric deficit diet and at least 150 minutes of physical activity per week. This integrated approach reflects real-world clinical practice where pharmacological treatment is always combined with lifestyle and dietary measures.
Key Results: Historic Figures
The 72-week results exceeded the medical community’s expectations:
- Tirzepatide 5 mg: average weight loss of 15.0% (vs 3.1% with placebo)
- Tirzepatide 10 mg: average weight loss of 19.5%
- Tirzepatide 15 mg: average weight loss of 20.9%
In absolute terms, this represents an average weight loss of 16 to 23 kg depending on the dose, for an average initial weight of 104 kg. At the maximum dose of 15 mg, nearly 57% of participants lost more than 20% of their body weight, and 36% lost more than 25%. These proportions are unprecedented for a pharmacological treatment.
Comparison with Existing Treatments
To put these results into perspective, here are the weight losses achieved in pivotal trials of other anti-obesity treatments:
- Orlistat (Xenical): approximately 3-4% additional weight loss vs placebo
- Liraglutide (Saxenda): approximately 5-8% weight loss
- Semaglutide (Wegovy): approximately 15-17% weight loss (STEP-1 study)
- Tirzepatide (SURMOUNT-1): 15 to 21% weight loss
Tirzepatide therefore offers a 4 to 5 percentage point advantage over semaglutide, its closest competitor. This difference is clinically significant and is explained by tirzepatide’s dual GIP/GLP-1 mechanism.
Metabolic Benefits Beyond Weight
SURMOUNT-1 also documented impressive metabolic improvements in non-diabetic participants:
- Waist circumference: reduction of 14.5 cm to 17.5 cm depending on the dose (reflecting visceral fat loss)
- Systolic blood pressure: reduction of 6.2 to 7.4 mmHg
- Triglycerides: reduction of 20 to 25%
- Fasting insulin: reduction of 41 to 52%
- C-reactive protein (inflammation marker): significant reduction
These improvements suggest that tirzepatide reduces overall cardiovascular risk, a hypothesis currently being tested in the SURPASS-CVOT study. The reduction in insulin resistance is particularly notable, as it could prevent progression to type 2 diabetes in prediabetic patients.
Tolerability Profile: Documented Side Effects
The most frequent side effects were gastrointestinal, consistent with the known profile of GLP-1 agonists:
- Nausea: 24% to 33% (vs 9% with placebo), mostly transient during titration
- Diarrhea: 16% to 23%
- Constipation: 11% to 17%
- Vomiting: 5% to 9%
The discontinuation rate due to adverse events was 4.3% to 7.1% with tirzepatide, compared to 2.6% with placebo. The majority of gastrointestinal events occurred during the first few weeks of treatment and attenuated over time. The progressive titration protocol (2.5 mg for 4 weeks, then increases in 2.5 mg increments) helps minimize these effects.
Study Limitations and Open Questions
Like any clinical trial, SURMOUNT-1 has limitations. The 72-week duration does not allow for evaluation of very long-term effects. The studied population was predominantly female (67%) and Caucasian (71%), limiting the generalizability of the results. Furthermore, the study excluded diabetic patients, who were treated in SURMOUNT-2.
The question of maintaining weight loss after treatment discontinuation remains open. Data from SURMOUNT-4 show that patients who stop tirzepatide regain approximately 50% of the lost weight within one year, highlighting the need for long-term treatment for most patients.
Tracking your weight and metabolic parameters is essential to evaluate your response to treatment. The MounjaGO app allows for precise daily tracking with report generation for your doctor.
FAQ: SURMOUNT-1 Study
Does SURMOUNT-1 concern diabetic patients?
No, SURMOUNT-1 deliberately excluded patients with type 2 diabetes. These patients are studied in SURMOUNT-2, which showed similar results with an additional significant improvement in glycemic control.
Is 20% weight loss realistic in clinical practice?
Results in clinical practice are generally slightly lower than in clinical trials (approximately 15-18% on average). However, with good nutritional support and regular physical activity, SURMOUNT-1 results are achievable for the majority of patients.
Which tirzepatide dose is most effective?
The 15 mg dose offers the best efficacy (20.9% weight loss), but the 10 mg dose (19.5%) offers an excellent efficacy/tolerability ratio. Your doctor will determine the optimal dose based on your individual response and tolerability.